USD 422
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| VRTX | 1.2 | 3.9 | -10.1 | -15.4 | -13.6 | -2.7 | 82.6 | 78.9 | 238.3 | 9277.8 |
| S&P 500 | 1.0 | 1.8 | -0.9 | 2.7 | 7.3 | 26.5 | 31.0 | 80.1 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | VRTX |
| name | Vertex Pharmaceuticals Incorporated |
| price | 422 |
| changes percentage | 1.2087 |
| change | 5.04 |
| day low | 419.27 |
| day high | 428.25 |
| year high | 519.88 |
| year low | 377.85 |
| market cap | 108677238000 |
| price avg 50 | 448.477 |
| price avg 200 | 457.22736 |
| exchange | NASDAQ |
| volume | 1707943 |
| avg volume | 1526047 |
| open | 422.73 |
| previous close | 416.96 |
| eps | -1.92 |
| pe | -219.79 |
| earnings announcement | 2025-02-03T10:59:00.000+0000 |
| shares outstanding | 257529000 |
| timestamp | 2025-01-17 21:00:00 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000875320 | |||
| revenue | 9869200000 | 8930700000 | 10.51 |
| gross profit | 8607000000 | 7850400000 | 9.64 |
| gross profit ratio | 0.87 | 0.88 | -0.79 |
| research and development expenses | 3162900000 | 2540300000 | 24.51 |
| operating expenses | 4775000000 | 3485000000 | 37.02 |
| interest income | 614700000 | 144600000 | 325.10 |
| interest expense | 44100000 | 54800000 | -19.53 |
| ebitda | 4605200000 | 4435500000 | 3.83 |
| ebitdaratio | 0.47 | 0.49 | -4.09 |
| operating income | 4307500000 | 4307400000 | 0.00 |
| operating income ratio | 0.44 | 0.48 | -9.51 |
| net income | 3619600000 | 3322000000 | 8.96 |
| net income ratio | 0.37 | 0.37 | -1.40 |
| eps | 14.05 | 12.97 | 8.33 |
Revenue Growth: revenue increased to 9,869 million in 2023 from 8,931 million in 2022 representing a change of 10.51%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 8,607 million in 2023 from 7,850 million in 2022 representing a change of 9.64%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 3,163 million in 2023 from 2,540 million in 2022 representing a change of 24.51%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 4,605 million in 2023 from 4,436 million in 2022 representing a change of 3.83%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 4,308 million in 2023 from 4,307 million in 2022 representing a change of 0.0%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to 3,620 million in 2023 from 3,322 million in 2022 representing a change of 8.96%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 14.05 in 2023 from 14.05 in 2022 representing a change of 8.33%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 4,775 million in 2023 from 3,485 million in 2022 representing a change of 37.02%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000875320 | |||
| revenue | 2771900000 | 2634700000 | 5.21 |
| gross profit | 2379300000 | 2262800000 | 5.15 |
| gross profit ratio | 0.86 | 0.86 | -0.06 |
| research and development expenses | 875900000 | 5415700000 | -83.83 |
| operating expenses | 1263000000 | 5787900000 | -78.18 |
| interest income | 132200000 | 156500000 | -15.53 |
| interest expense | 7500000 | 9900000 | -24.24 |
| ebitda | 1284800000 | -3327300000 | 138.61 |
| ebitdaratio | 0.46 | -1.32 | 135.18 |
| operating income | 1116300000 | -3525100000 | 131.67 |
| operating income ratio | 0.4 | -1.34 | 130.10 |
| net income | 1045400000 | -3593600000 | 129.09 |
| net income ratio | 0.38 | -1.36 | 127.65 |
| eps | 4.05 | -13.92 | 129.09 |
Revenue Growth: revenue increased to 2,772 million in 2024Q3 from 2,635 million in 2024Q2 representing a change of 5.21%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 2,379 million in 2024Q3 from 2,263 million in 2024Q2 representing a change of 5.15%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 876 million in 2024Q3 from 5,416 million in 2024Q2 representing a change of -83.83%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 1,263 million in 2024Q3 from 5,788 million in 2024Q2 representing a change of -78.18%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 1,285 million in 2024Q3 from -3,327 million in 2024Q2 representing a change of 138.61%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 1,116 million in 2024Q3 from -3,525 million in 2024Q2 representing a change of 131.67%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to 1,045 million in 2024Q3 from -3,594 million in 2024Q2 representing a change of 129.09%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 4.05 in 2024Q3 from 4.05 in 2024Q2 representing a change of 129.09%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000875320 | |||
| total assets | 22730200000 | 18150900000 | 25.23 |
| total liabilities | 5149800000 | 4238200000 | 21.51 |
| total equity | 17580400000 | 13912700000 | 26.36 |
| cash and cash equivalents | 10369100000 | 10504000000 | -1.28 |
| short term investments | 849200000 | 274500000 | 209.36 |
| long term investments | 2596400000 | 99400000 | 2512.07 |
| total current assets | 14144200000 | 12681300000 | 11.54 |
| total non current assets | 8586000000 | 5469600000 | 56.98 |
| total current liabilities | 3547400000 | 2430600000 | 45.95 |
| total non current liabilities | 1602400000 | 1807600000 | -11.35 |
| common stock | 2600000 | 2600000 | 0.00 |
| retained earnings | 10142400000 | 6522800000 | 55.49 |
| total debt | 808400000 | 561000000 | 44.10 |
Total Assets: Total Assets increased to 22,730 million in 2023 from 18,151 million in 2022 representing a change of 25.23%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 17,580 million in 2023 from 13,913 million in 2022 representing a change of 26.36%. This indicates an increase in shareholders' equity.
Short Term Investments: Short Term Investments increased to 849 million in 2023 from 274 million in 2022 representing a change of 209.36%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 14,144 million in 2023 from 12,681 million in 2022 representing a change of 11.54%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to 10,142 million in 2023 from 6,523 million in 2022 representing a change of 55.49%. This indicates an accumulated profits.
Total Liabilities: Total Liabilities increased to 5,150 million in 2023 from 4,238 million in 2022 representing a change of 21.51%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 10,369 million in 2023 from 10,504 million in 2022 representing a change of -1.28%. This indicates a decrease in available liquid assets.
Total Current Liabilities: Total Current Liabilities increased to 3,547 million in 2023 from 2,431 million in 2022 representing a change of 45.95%. This indicates a higher short-term debt burden.
Total Debt: Total Debt increased to 808 million in 2023 from 561 million in 2022 representing a change of 44.1%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000875320 | |||
| total assets | 22240200000 | 20132100000 | 10.47 |
| total liabilities | 6609300000 | 5357400000 | 23.37 |
| total equity | 15630900000 | 14774700000 | 5.80 |
| cash and cash equivalents | 5239200000 | 4580100000 | 14.39 |
| short term investments | 1285300000 | 1215400000 | 5.75 |
| long term investments | 4703500000 | 4397900000 | 6.95 |
| total current assets | 9804100000 | 8941600000 | 9.65 |
| total non current assets | 12436100000 | 11190499999 | 11.13 |
| total current liabilities | 3973100000 | 3547200000 | 12.01 |
| total non current liabilities | 2636200000 | 1810199999 | 45.63 |
| common stock | 2600000 | 2600000 | 0.00 |
| retained earnings | 8693800000 | 7648400000 | 13.67 |
| total debt | 1702900000 | 933400000 | 82.44 |
Total Assets: Total Assets increased to 22,240 million in 2024Q3 from 20,132 million in 2024Q2 representing a change of 10.47%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 15,631 million in 2024Q3 from 14,775 million in 2024Q2 representing a change of 5.8%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 5,239 million in 2024Q3 from 4,580 million in 2024Q2 representing a change of 14.39%. This indicates an increase in available liquid assets.
Short Term Investments: Short Term Investments increased to 1,285 million in 2024Q3 from 1,215 million in 2024Q2 representing a change of 5.75%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 9,804 million in 2024Q3 from 8,942 million in 2024Q2 representing a change of 9.65%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to 8,694 million in 2024Q3 from 7,648 million in 2024Q2 representing a change of 13.67%. This indicates an accumulated profits.
Total Liabilities: Total Liabilities increased to 6,609 million in 2024Q3 from 5,357 million in 2024Q2 representing a change of 23.37%. This indicates an increase in overall liabilities.
Total Current Liabilities: Total Current Liabilities increased to 3,973 million in 2024Q3 from 3,547 million in 2024Q2 representing a change of 12.01%. This indicates a higher short-term debt burden.
Total Debt: Total Debt increased to 1,703 million in 2024Q3 from 933 million in 2024Q2 representing a change of 82.44%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000875320 | |||
| net change in cash | -139700000 | 3711900000 | -103.76 |
| operating cash flow | 3537300000 | 4129900000 | -14.35 |
| free cash flow | 3278900001 | 3925200000 | -16.47 |
| capital expenditure | -258399999 | -204700000 | -26.23 |
| depreciation and amortization | 181300000 | 148300000 | 22.25 |
| deferred income tax | -536500000 | -275900000 | -94.45 |
| stock based compensation | 581200000 | 491300000 | 18.30 |
| accounts payables | 48700000 | 120800000 | -59.69 |
| inventory | -322900000 | -136400000 | -136.73 |
| acquisitions net | 0 | -295900000 | 100.00 |
| investments in property plant and equipment | -200400000 | -204700000 | 2.10 |
| net cash used for investing activites | -3141700000 | -321100000 | -878.42 |
| debt repayment | -43100000 | -82000000 | 47.44 |
| common stock issued | 0 | 186300000 | -100.00 |
| common stock repurchased | -653700000 | -172000000 | -280.06 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -562200000 | -67700000 | -730.43 |
| cash at end of period | 10372300000 | 10512000000 | -1.33 |
| accounts receivables | -84100000 | -358600000 | 76.55 |
| cash at beginning of period | 10512000000 | 6800100000 | 54.59 |
Net Change in Cash: Net Change in Cash decreased to -140 million in 2023 from 3,712 million in 2022 representing a change of -103.76%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to 3,537 million in 2023 from 4,130 million in 2022 representing a change of -14.35%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 3,279 million in 2023 from 3,925 million in 2022 representing a change of -16.47%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 581 million in 2023 from 491 million in 2022 representing a change of 18.3%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to -84 in 2023 from -359 million in 2022 representing a change of 76.55%. This suggests that the company is less capable of collecting payments from its customers.
Capital Expenditure: Capital Expenditure decreased to -258 million in 2023 from -205 million in 2022 representing a change of -26.23%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 49 million in 2023 from 121 million in 2022 representing a change of -59.69%. This indicates that the company has reduced its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000875320 | |||
| operating cash flow | 1369800000 | -3753600000 | 136.49 |
| free cash flow | 1489800000 | -3830300000 | 138.90 |
| capital expenditure | 120000000 | -76700000 | 256.45 |
| depreciation and amortization | 53200000 | 54000000 | -1.48 |
| deferred income tax | -123300000 | -118800000 | -3.79 |
| stock based compensation | 184600000 | 154200000 | 19.71 |
| accounts receivables | -51800000 | 135100000 | -138.34 |
| accounts payables | 66100000 | -25100000 | 363.35 |
| inventory | -182500000 | -107200000 | -70.24 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -67700000 | -76700000 | 11.73 |
| net cash used for investing activites | -348000000 | -463700000 | 24.95 |
| debt repayment | -5400000 | -13700000 | 60.58 |
| common stock issued | 8400000 | 0 | NaN |
| common stock repurchased | -391400000 | -400800000 | 2.35 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -387500000 | -358600000 | -8.06 |
| net change in cash | 668000000 | -4577900000 | 114.59 |
| cash at end of period | 5248100000 | 4580100000 | 14.58 |
| cash at beginning of period | 4580100000 | 9158000000 | -49.99 |
Net Change in Cash: Net Change in Cash increased to 668 million in 2024Q3 from -4,578 million in 2024Q2 representing a change of 114.59%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 1,370 million in 2024Q3 from -3,754 million in 2024Q2 representing a change of 136.49%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 1,490 million in 2024Q3 from -3,830 million in 2024Q2 representing a change of 138.9%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Receivables: Accounts Receivables decreased to -52 million in 2024Q3 from 135 million in 2024Q2 representing a change of -138.34%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Capital Expenditure: Capital Expenditure increased to 120 million in 2024Q3 from -77 million in 2024Q2 representing a change of 256.45%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 185 million in 2024Q3 from 154 million in 2024Q2 representing a change of 19.71%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 66 million in 2024Q3 from 25 million in 2024Q2 representing a change of 363.35%. This indicates that the company has increased its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 38.3 | 34.87 | 9.82 |
| net income per share | 14.05 | 12.97 | 8.28 |
| operating cash flow per share | 13.73 | 16.13 | -14.88 |
| free cash flow per share | 12.72 | 15.33 | -16.98 |
| cash per share | 43.53 | 42.09 | 3.43 |
| book value per share | 68.22 | 54.33 | 25.58 |
| tangible book value per share | 60.74 | 47.72 | 27.28 |
| shareholders equity per share | 68.22 | 54.33 | 25.58 |
| interest debt per share | 3.31 | 2.4 | 37.58 |
| market cap | 104855553000 | 73956558000 | 41.78 |
| enterprise value | 95294853000 | 64013558000 | 48.87 |
| pe ratio | 28.97 | 22.26 | 30.12 |
| price to sales ratio | 10.62 | 8.28 | 28.30 |
| pocfratio | 29.64 | 17.91 | 65.53 |
| pfcf ratio | 31.98 | 18.84 | 69.73 |
| pb ratio | 5.96 | 5.32 | 12.20 |
| ptb ratio | 5.96 | 5.32 | 12.20 |
| ev to sales | 9.66 | 7.17 | 34.71 |
| enterprise value over ebitda | 20.69 | 14.43 | 43.38 |
| ev to operating cash flow | 26.94 | 15.5 | 73.81 |
| ev to free cash flow | 29.06 | 16.31 | 78.21 |
| earnings yield | 0.03 | 0.04 | -23.15 |
| free cash flow yield | 0.03 | 0.05 | -41.08 |
| debt to equity | 0.05 | 0.04 | 14.04 |
| debt to assets | 0.04 | 0.03 | 15.07 |
| net debt to ebitda | -2.08 | -2.24 | 7.39 |
| current ratio | 3.99 | 5.22 | -23.58 |
| interest coverage | 97.68 | 78.6 | 24.27 |
| income quality | 0.98 | 1.24 | -21.39 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.32 | 0.28 | 12.67 |
| intangibles to total assets | 0.08 | 0.09 | -8.99 |
| capex to operating cash flow | 0.07 | 0.05 | 47.38 |
| capex to revenue | 0.03 | 0.02 | 14.23 |
| capex to depreciation | 1.43 | 1.38 | 3.26 |
| stock based compensation to revenue | 0.06 | 0.06 | 7.05 |
| graham number | 146.83 | 125.92 | 16.61 |
| roic | 0.18 | 0.21 | -13.60 |
| return on tangible assets | 0.17 | 0.2 | -13.79 |
| graham net net | 29.53 | 30.66 | -3.68 |
| working capital | 10596800000 | 10250700000 | 3.38 |
| tangible asset value | 15652500000 | 12221100000 | 28.08 |
| net current asset value | 8994400000 | 8443100000 | 6.53 |
| invested capital | 13977600000 | 13050700000 | 7.10 |
| average receivables | 1502800000 | 1289500000 | 16.54 |
| average payables | 334400000 | 249450000 | 34.05 |
| average inventory | 599700000 | 406850000 | 47.40 |
| days sales outstanding | 57.82 | 58.94 | -1.90 |
| days payables outstanding | 105.52 | 102.68 | 2.77 |
| days of inventory on hand | 213.64 | 155.62 | 37.28 |
| receivables turnover | 6.31 | 6.19 | 1.94 |
| payables turnover | 3.46 | 3.55 | -2.69 |
| inventory turnover | 1.71 | 2.35 | -27.16 |
| roe | 0.21 | 0.24 | -13.77 |
| capex per share | 1.0 | 0.8 | 25.45 |
ROE: Return on Equity (ROE) decreased to 0.21 on 2023-12-31 from 0.24 on 2022-12-31, representing a change of -13.77%. However, ROE is >= 15%, suggesting that the company has been generating high returns for its shareholders still.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.05 on 2023-12-31 from 0.04 on 2022-12-31, representing a change of 14.04%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 28.97 on 2023-12-31 from 22.26 on 2022-12-31, representing a change of 30.12%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 3.99 on 2023-12-31 from 5.22 on 2022-12-31, representing a change of -23.58%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| VRTX | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 10.74 | 10.21 | 5.25 |
| net income per share | 4.05 | -13.92 | 129.10 |
| operating cash flow per share | 5.31 | -14.54 | 136.51 |
| free cash flow per share | 5.77 | -14.84 | 138.91 |
| cash per share | 25.29 | 22.45 | 12.62 |
| book value per share | 60.58 | 57.24 | 5.84 |
| tangible book value per share | 53.14 | 49.78 | 6.75 |
| shareholders equity per share | 60.58 | 57.24 | 5.84 |
| interest debt per share | 6.63 | 3.65 | 81.39 |
| market cap | 119990640000 | 121629625000 | -1.35 |
| enterprise value | 116454340000 | 117982925000 | -1.30 |
| pe ratio | 28.69 | -8.46 | 439.12 |
| price to sales ratio | 43.29 | 46.16 | -6.23 |
| pocfratio | 87.6 | -32.4 | 370.33 |
| pfcf ratio | 80.54 | -31.75 | 353.64 |
| pb ratio | 7.68 | 8.23 | -6.75 |
| ptb ratio | 7.68 | 8.23 | -6.75 |
| ev to sales | 42.01 | 44.78 | -6.18 |
| enterprise value over ebitda | 90.64 | -35.46 | 355.62 |
| ev to operating cash flow | 85.02 | -31.43 | 370.48 |
| ev to free cash flow | 78.17 | -30.8 | 353.77 |
| earnings yield | 0.01 | -0.03 | 129.49 |
| free cash flow yield | 0.01 | -0.03 | 139.43 |
| debt to equity | 0.11 | 0.06 | 72.45 |
| debt to assets | 0.08 | 0.05 | 65.15 |
| net debt to ebitda | -2.75 | 1.1 | -351.13 |
| current ratio | 2.47 | 2.52 | -2.11 |
| interest coverage | 148.84 | -356.07 | 141.80 |
| income quality | 1.31 | 1.04 | 25.45 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.32 | 2.06 | -84.63 |
| intangibles to total assets | 0.09 | 0.1 | -9.76 |
| capex to operating cash flow | 0.09 | -0.02 | 528.72 |
| capex to revenue | 0.04 | 0.03 | 48.71 |
| capex to depreciation | 2.26 | 1.42 | 58.81 |
| stock based compensation to revenue | 0.07 | 0.06 | 13.79 |
| graham number | 74.32 | 133.91 | -44.50 |
| roic | 0.05 | -0.23 | 123.17 |
| return on tangible assets | 0.05 | -0.2 | 126.06 |
| graham net net | 6.85 | 8.28 | -17.25 |
| working capital | 5831000000 | 5394400000 | 8.09 |
| tangible asset value | 13711300000 | 12849200000 | 6.71 |
| net current asset value | 3194800000 | 3584200000 | -10.86 |
| invested capital | 10264500000 | 9090600000 | 12.91 |
| average receivables | 1703350000 | 1724650000 | -1.24 |
| average payables | 361850000 | 339650000 | 6.54 |
| average inventory | 997200000 | 863850000 | 15.44 |
| days sales outstanding | 56.84 | 56.57 | 0.47 |
| days payables outstanding | 90.73 | 79.35 | 14.34 |
| days of inventory on hand | 247.53 | 221.33 | 11.84 |
| receivables turnover | 1.58 | 1.59 | -0.47 |
| payables turnover | 0.99 | 1.13 | -12.54 |
| inventory turnover | 0.36 | 0.41 | -10.58 |
| roe | 0.07 | -0.24 | 127.50 |
| capex per share | 0.47 | 0.3 | 56.51 |
ROE:
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 28.69 on 2024-09-30 Q3 from -8.46 on 2024-06-30 Q2, representing a change of 439.12%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 2.47 on 2024-09-30 Q3 from 2.52 on 2024-06-30 Q2, representing a change of -2.11%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.11 on 2024-09-30 Q3 from 0.06 on 2024-06-30 Q2, representing a change of 72.45%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Positive Sentiment: Discounted Cash Flow value is 642.57 which is higher than current price 422, indicates the company may be undervalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2025-01-16 08:00:00
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Sentiment: Positive
Publish Date: 2025-01-16 07:53:12
Vertex Pharmaceuticals NASDAQ: VRTX is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the pain management sector, presenting a compelling growth opportunity for the company and its investors.
Sentiment: Positive
Publish Date: 2025-01-16 05:49:00
It usually doesn't matter if you buy a given stock immediately or two weeks later. Sure, the stock could move up or down but typically not enough to matter all that much.
Sentiment: Negative
Publish Date: 2025-01-15 10:01:30
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Sentiment: Negative
Publish Date: 2025-01-15 07:25:00
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Sentiment: Positive
Publish Date: 2025-01-14 14:47:09
On Sunday, Vertex Pharmaceuticals Incorporated VRTX announced multiple program updates, including:
Sentiment: Negative
Publish Date: 2025-01-14 07:25:00
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Sentiment: Neutral
Publish Date: 2025-01-13 12:16:38
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ET Company Participants Dr. Reshma Kewalramani - President and CEO Charlie Wagner - Chief Financial Officer Stuart Arbuckle - Chief Operating Officer David Altshuler - Chief Scientific Officer Conference Call Participants Jessica Fye - J.P.
Sentiment: Negative
Publish Date: 2025-01-13 07:30:00
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Sentiment: Positive
Publish Date: 2025-01-13 04:48:00
Arguably the three most important words in investing are: I don't know. Acknowledging that you don't know for sure what will happen with any investment can save you from a heap of trouble.
Sentiment: Positive
Publish Date: 2025-01-12 17:01:00
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 a.m. ET/7:30 a.m. PT. “2024 marked another year of excellent progress for Vertex, as we reached more people with CF than ever before, began a new era of commercial diversification, and advanced and b.
Sentiment: Positive
Publish Date: 2025-01-10 12:51:31
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?
Sentiment: Positive
Publish Date: 2025-01-10 07:30:00
BOSTON & SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and.
Sentiment: Positive
Publish Date: 2025-01-10 07:30:00
SHANGHAI & CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and.
Sentiment: Negative
Publish Date: 2025-01-10 07:25:00
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Sentiment: Negative
Publish Date: 2025-01-09 07:25:00
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Sentiment: Positive
Publish Date: 2025-01-08 03:00:00
Pharmaceutical stocks represent an interesting prospect — while it is incredibly tough to separate the wheat from the chaff, picking a winner early on is more or less a ticket to outsized returns.
Sentiment: Negative
Publish Date: 2025-01-07 12:23:18
Vertex Pharmaceuticals Inc VRTX is grappling with bearish technical signals as its stock forms a dreaded Death Cross.
Sentiment: Positive
Publish Date: 2025-01-07 08:46:14
Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA approval for the first CRSPR-based gene therapy treatment for sickle cell anemia (SCA) called Casgevy, developed by Vertex Pharmaceuticals Inc. NASDAQ: VRTX.
Sentiment: Positive
Publish Date: 2025-01-07 07:00:00
-- Collaboration to leverage Orna's differentiated lipid nanoparticle (LNP) delivery solutions for patients with SCD and TDT -- -- Orna to receive an upfront payment and is eligible to receive potential pre-clinical, clinical, and commercialization milestone payments and royalties -- WATERTOWN, Mass. , Jan. 7, 2025 /PRNewswire/ -- Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a three-year strategic research collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to utilize Orna's novel and proprietary LNP delivery solutions to enhance Vertex's efforts in developing next generation gene editing therapies for patients with SCD and TDT.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
